The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Orai1 contributes to the establishment of an apoptosis-resistant phenotype in prostate cancer cells
Open accessAbstract
The molecular nature of calcium (Ca(2+))-dependent mechanisms and the ion channels having a major role in the apoptosis of cancer cells remain a subject of debate. Here, we show that the recently identified Orai1 protein represents the major molecular component of endogenous store-operated Ca(2+) entry (SOCE) in human prostate cancer (PCa) cells, and constitutes the principal source of Ca(2+) influx used by the cell to trigger apoptosis. The downregulation of Orai1, and consequently SOCE, protects the cells from diverse apoptosis-inducing pathways, such as those induced by thapsigargin (Tg), tumor necrosis factor α, and cisplatin/oxaliplatin. The transfection of functional Orai1 mutants, such as R91W, a selectivity mutant, and L273S, a coiled-coil mutant, into the cells significantly decreased both SOCE and the rate of Tg-induced apoptosis. This suggests that the functional coupling of STIM1 to Orai1, as well as Orai1 Ca(2+)-selectivity as a channel, is required for its pro-apoptotic effects. We have also shown that the apoptosis resistance of androgen-independent PCa cells is associated with the downregulation of Orai1 expression as well as SOCE. Orai1 rescue, following Orai1 transfection of steroid-deprived cells, re-established the store-operated channel current and restored the normal rate of apoptosis. Thus, Orai1 has a pivotal role in the triggering of apoptosis, irrespective of apoptosis-inducing stimuli, and in the establishment of an apoptosis-resistant phenotype in PCa cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Cited by
Ion Channels in Cancer: Are Cancer Hallmarks Oncochannelopathies?
Prevarskaya, N., Skryma, R., & Shuba, Y. (2018) · Physiological Reviews · doi:10.1152/physrev.00044.2016 · Cited by 484
Self-citationCalcium Channels and Pumps in Cancer: Changes and Consequences
Monteith, G. R., Davis, F. M., & Roberts-Thomson, S. J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.r112.343061 · Cited by 388
Marchi, S., Giorgi, C., Galluzzi, L., & Pinton, P. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.017 · Cited by 235
Cell Volume Regulation in Epithelial Physiology and Cancer
Pedersen, S. F., Hoffmann, E. K., & Novak, I. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00233 · Cited by 94
STIM-Orai Channels and Reactive Oxygen Species in the Tumor Microenvironment
Frisch, J., Angenendt, A., Hoth, M., Prates Roma, L., & Lis, A. (2019) · Cancers · doi:10.3390/cancers11040457 · Cited by 68
Metadata
- Authors
- Flourakis, M., Lehen'kyi, V, Beck, B., Raphaël, M., Vandenberghe, M., Abeele, F. V., Roudbaraki, M., Lepage, G., Mauroy, B., Romanin, C., Shuba, Y., Skryma, R., & Prevarskaya, N.
- Venue
- Cell Death & Disease
- Published
- 2010-09-16
- Volume
- 1
- Issue
- 9
- Pages
- e75-e75
- ISSN
- 2041-4889 (ISSN-L)
- OpenAlex
- W2005700813
- Cited by
- 212
- References
- 1
- FWCI
- 5.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Orai1 contributes to the establishment of an apoptosis-resistant phenotype in prostate cancer cells. https://app.cochat.ai/papers/10.1038/cddis.2010.52
- The paper
- Flourakis, M., Lehen'kyi, V, Beck, B., Raphaël, M., Vandenberghe, M., Abeele, F. V., Roudbaraki, M., Lepage, G., Mauroy, B., Romanin, C., Shuba, Y., Skryma, R., & Prevarskaya, N. (2010). Orai1 contributes to the establishment of an apoptosis-resistant phenotype in prostate cancer cells. Cell Death & Disease. https://doi.org/10.1038/cddis.2010.52
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.